

# 1    High-throughput Single-cell CNV Detection Reveals Clonal 2    Evolution During Hepatocellular Carcinoma Recurrence

3

4    Liang Wu<sup>1,2,3,#,\*</sup>, Yuzhou Wang<sup>2,#</sup>, Miaomiao Jiang<sup>2,#</sup>, Biaofeng Zhou<sup>1,2,3</sup>, Yunfan  
5    Sun<sup>4</sup>, Kaiqian Zhou<sup>4</sup>, Jiarui Xie<sup>2,3,5</sup>, Yu Zhong<sup>2,3,5</sup>, Zhikun Zhao<sup>2</sup>, Michael Dean<sup>6</sup>,  
6    Yong Hou<sup>1,2,3</sup>, Shiping Liu<sup>1,2,3,\*</sup>

7

8    <sup>1</sup> *BGI Education Center, University of Chinese Academy of Sciences, Shenzhen  
9    518083, China*

10    <sup>2</sup> *BGI-Shenzhen, Beishan Industrial Zone, Shenzhen 518083, China*

11    <sup>3</sup> *Shenzhen Key Laboratory of Single-Cell Omics, BGI-Shenzhen, Shenzhen 518100,  
12    China*

13    <sup>4</sup> *Department of Liver Surgery & Transplantation, Liver Cancer Institute, Zhongshan  
14    Hospital, Fudan University; Key Laboratory of Carcinogenesis and Cancer Invasion,  
15    Ministry of Education, Shanghai 200032, China*

16    <sup>5</sup> *School of Biology and Biological Engineering, South China University of  
17    Technology, Guangzhou 510640, China*

18    <sup>6</sup> *Laboratory of Translational Genomics, Division of Cancer Epidemiology &  
19    Genetics, National Cancer Institute, Gaithersburg, MD 20877, USA*

20

21    <sup>#</sup> Equal contribution.

22    <sup>\*</sup> Corresponding authors.

23    E-mail: [wuliang@genomics.cn](mailto:wuliang@genomics.cn) (Wu L), [liushiping@genomics.cn](mailto:liushiping@genomics.cn) (Liu SP).

24

25

26 **Abstract**

27 Single-cell genomics provides substantial resources for dissecting cellular  
28 heterogeneity and cancer evolution, but classical DNA amplification-based methods  
29 are low-throughput and introduce coverage bias during sample preamplification. We  
30 developed a single-cell DNA library preparation method without preamplification in  
31 nanolitre scale (scDPN). The method has a throughput of up to 1,800 cells per run for  
32 copy number variation (CNV) detection. Also, it has a lower level of amplification  
33 bias and noise than the multiple displacement amplification (MDA) method and  
34 showed high sensitivity and accuracy based on evaluation in cell lines and tumour  
35 tissues. We used this approach to profile the tumour clones in paired primary and  
36 relapsed tumour samples of hepatocellular carcinoma (HCC). We identified 3 clonal  
37 subpopulations with a multitude of aneuploid alterations across the genome.  
38 Furthermore, we observed that a minor clone of the primary tumour containing  
39 additional alterations in chromosomes 1q, 10q, and 14q developed into the dominant  
40 clone in the recurrent tumour, indicating clonal selection during recurrence in HCC.  
41 Overall, this approach provides a comprehensive and scalable solution to understand  
42 genome heterogeneity and evolution.

43

44 **KEYWORDS:** Single-cell sequencing; Hepatocellular carcinoma; Heterogeneity;  
45 Clonal evolution; Relapse

46

47 **Introduction**

48 Heterogeneity is pervasive in human cancer [1] and manifests as morphologic,  
49 transcriptomic, and genetic differences between cells. However, intercellular genetic  
50 heterogeneity in cell populations is often obscured in genome analysis at the bulk  
51 level. Single-cell technologies have advanced rapidly in the past decade and can  
52 detect variants at the single-cell level [2-4]. Technologies for transcriptome analysis  
53 have been used to profile intra-tumour heterogeneity or define immune infiltration in  
54 various cancer types [5-13]. Although less widely utilized due to throughput and cost  
55 limitations, single-cell genome sequencing is a powerful tool to track clonal dynamics  
56 and infer evolutionary trajectories [14-18].

57 Most strategies for single-cell whole-genome sequencing (WGS) require  
58 whole-genome amplification (WGA) before library construction, which introduces  
59 bias and increases cost. The degenerate oligonucleotide-primed PCR (DOP-PCR)  
60 method attempts to amplify the entire single-cell genome by random oligonucleotide  
61 priming [19]. However, it preferentially amplifies regions rich in cytosine and  
62 guanosine, resulting in lower genomic coverage. Multiple displacement amplification  
63 (MDA) is another commonly used avenue utilizing random primers and the high  
64 fidelity φ29 polymerase. This method generates data with good genome coverage and  
65 lower error rates. However, due to the polymerase's strand displacement activity [20],  
66 compromised uniformity is not suitable for copy number variation (CNV) detection.  
67 A hybrid method called multiple annealing and looping based amplification cycles  
68 (MALBAC) amplifies the genome with random primers and creates looped precursors  
69 to prevent continuous amplification before the PCR, achieving a better uniformity  
70 [21]. The other category of single-cell genome sequencing approaches is  
71 preamplification-free and transposase-based, including linear amplification via  
72 transposon insertion (LIANTI) [22], direct library preparation (DLP) [23], and  
73 transposon barcoded (TnBC) methods [24]. These approaches transpose single-cell  
74 genomic DNA directly and add common sequences to the end of the fragments for

75 further amplification, reducing biases compared with preamplification-based  
76 techniques. These methods are based on a single tube or use complicated  
77 microvalve-based microfluidic chips, limiting the throughput.

78 Hepatocellular carcinoma (HCC) is a high-grade malignancy with a high  
79 recurrence rate of up to approximately 60% within 5 years [25]. As a risk factor for  
80 reduced survival, early recurrence of HCC is ascribed to a residual tumour and  
81 intrahepatic micrometastasis, closely related to intra-tumour heterogeneity [26].  
82 Next-generation sequencing (NGS) studies based on cell population have reported a  
83 high degree of intra-tumour heterogeneity in HCC [27, 28]. A single-cell triple-omics  
84 approach applied to 26 tumour cells from HCC identified 2 tumour clones based on  
85 their CNV profiles [29]. Also, monoclonal and polyclonal origins have been reported  
86 recently based on single-cell WGS of ~ 30 cells in two individual patients [30].  
87 However, a large number of cells are required to more comprehensively understand  
88 the heterogeneity in HCC, clonal expansion, and selection during HCC relapse.

89 Here, we developed an unbiased preamplification-free single-cell DNA library  
90 preparation in nanolitre scale (scDPN) method using microwell chips and a  $72 \times 72$   
91 dual indexing strategy, which is capable of processing up to ~1,800 single cells in  
92 parallel. This approach can obtain highly sensitive and accurate single-cell CNV  
93 (scCNV) profiles based on evaluations in cell lines and tumour samples. We further  
94 applied this approach to paired primary and relapsed HCC tumour samples from the  
95 same patient. We identified 3 clonal subpopulations with aneuploid alterations across  
96 the genome. Furthermore, we noticed that relapsed tumour cells were originated from  
97 a minor subpopulation of the primary tumour, indicating clonal selection during HCC  
98 recurrence.

99 **Results**

100 **Microwell-based single-cell DNA library preparation workflow**

101 To increase scCNV detection efficiency, we developed a preamplification-free and  
102 unbiased single-cell DNA library preparation approach called scDPN for

103 high-throughput scCNV detection, which provides a comprehensive, scalable solution  
104 for revealing genomic heterogeneity. The workflow of scDPN includes three main  
105 parts: cell isolation and single-cell identification, transposase-based (Tn5) library  
106 construction, and library pooling and sequencing. The first two steps were carried out  
107 in a 5,184 microwell chip (**Figure 1**). A cell suspension stained with Hoechst and  
108 propidium iodide (PI) was dispensed into the microwell chip with a MultiSample  
109 NanoDispenser (MSND). Cell suspensions with a range from 0.5 to 2.6 cells/50 nL  
110 (10~52 cells/ $\mu$ L) were optimum to obtain more than 1,000 wells with single-cell due  
111 to the cell counts per well followed a Poisson distribution. We used automated  
112 imaging to identify the number of cells and their viability, using fluorescent Hoechst  
113 and PI signals on a fluorescence microscope. Only microwells with single and viable  
114 cell (Hoechst<sup>+</sup>PI<sup>-</sup>) were selected for cell lysis and transposase fragmentation.  
115 Individual single-cell products were discriminated using  $72 \times 72$  paired barcoded  
116 primers dispensed in succession with two individual dispensing steps. After several  
117 cycles of PCR, the barcodes and sequencing adaptors were added to both ends of the  
118 fragmented DNA. The microwell chip was then inverted, and all the barcoded  
119 libraries were collected into a pooled library. We determined the size distribution of  
120 pooled single-cell libraries by Agilent 2100 analysis (Figure S1). The libraries were  
121 then purified and cyclized for single-end 100 bp (SE100) sequencing on BGISEQ-500  
122 [31].

123 **Assessment of data quality and uniformity under different reaction conditions**  
124 The HeLa S3 and YH cell lines, HCC adjacent normal liver tissue (ANT), and tumour  
125 tissues were processed and sequenced at  $0.02\times$  depth (~600k reads under SE100). To  
126 confirm whether our approach can generate enough data for scCNV detection, we  
127 draw a CNV saturation curve using three tumour cells with deeper sequencing depths  
128 up to  $0.15\times$  (**Figure 2A**, Materials and Methods). The number of detected CNVs  
129 increased in proportion to the number of randomly extracted uniquely mapped  
130 deduplicated reads (UMDR). When the amount of UMDR reached 300k, with an

131 average sequencing depth of 0.01 $\times$ , the detected CNV counts were saturated (Figure  
132 2A).

133 We tested a combination of transposase (T1, T2, T3) and proteinase (P1, P2)  
134 reaction conditions to optimize the protocol. Single-cell libraries with raw data above  
135 30k reads (5% of average reads) were assumed to have a template-based reaction, and  
136 148 cells from 5 conditions were qualified (Table S1). Afterward, we selected the  
137 cells with oversaturated reads (UMDR > 300k) for further accuracy assessment. It  
138 was evident that condition T2\_P1 (65%) showed the highest rate of cells passing the  
139 filtering criteria; conditions T1\_P1, T2\_P2, and T3\_P2 showed a medium utilization  
140 rate between 40%~50%; and T3\_P1 showed the lowest utilization rate, below 30%  
141 (Table S1). The qualified cells are listed in Table S2.

142 We statistically evaluated several features of these cells in different conditions,  
143 including mapped reads, coverage, duplication rates, and median absolute pairwise  
144 difference (MAPD) values. As the amount of sequencing reads affects these values,  
145 we down-sampled each single-cell library to 400k raw reads for comparison.  
146 Single-cell libraries treated with condition T3\_P1 showed significantly fewer mapped  
147 reads and lower coverage (Figure S2A). A low duplication ratio reflects high data  
148 utilization. Conditions T2\_P1, T2\_P2, or T3\_P2 had a mean duplication rate below  
149 20%, which were lower than T1\_P1 or T3\_P1 (**Figure 2B**).

150 As a measurement of the bin-to-bin variation in read coverage, MAPD is an  
151 indicator of the evenness of WGA. Conditions T2\_P1, T3\_P1, and T3\_P2 exhibited  
152 lower MAPD values ( $0.26 \pm 0.07$ ,  $0.26 \pm 0.03$ , and  $0.23 \pm 0.04$ , respectively, under 5k  
153 bins) compared with condition T1\_P1 ( $0.37 \pm 0.15$  under 5k bins,  $P < 0.05$ ) (Figure  
154 2B). All of these conditions showed a much lower MAPD (mean MAPD < 0.4, 0.34  
155 M mapping reads under a bin size of 300 kb) than that of normal cells prepared by  
156 MDA (MAPD: 0.4-0.6, 1.5 M mapped reads under a bin size of 500 kb [32]). We  
157 observed that CNV profiles generated from poor quality libraries had significant noise  
158 and larger MAPD values, so we set MAPD  $\leq 0.45$  as a cut-off for acceptable quality

159 according to previous reports [32]. Because aberrant chromosomes influence MAPD,  
160 we compared the utilization rates from the same HCC tumour tissue under different  
161 conditions. The results showed that T2\_P1 and T2\_P2 had higher utilization rates up  
162 to 100%, by using a selection criterion of  $MAPD \leq 0.45$  for bin sizes of 600 kb or 300  
163 kb (Figure S2B).

164 To further evaluate this approach's genome-wide uniformity, we drew Lorenz  
165 curves for each condition and the data generated by the MDA method [24]. There  
166 were no substantial differences between the five conditions, and they all showed  
167 better uniformity than the MDA method (Figure 2C). Besides, the Lorenz curves  
168 demonstrated that scDPN had comparable uniformity with DOP-PCR, MALBAC,  
169 LIANTI, TnBC, a single-cell sequencing method that combines combinatorial  
170 indexing and linear amplification (sci-L3) [33], and the 10x genomics CNV platform  
171 (Figure 2D). The T2\_P1 condition was chosen as optimal for further applications.

#### 172 **scDPN provides reliable data for accurate scCNV detection**

173 To assess the sensitivity and accuracy of CNV calling with a depth of 300k reads, we  
174 first generated analogue data of CNVs of different sizes (1~15 Mb), with 20  
175 variations generated for each size (Materials and Methods). Approximately 80% of  
176 CNVs above 2 Mb were detected in 5k, 10k, or 20k bins (Figure S3A). The false  
177 discovery rate (FDR) was between 0.3~0.4 when detecting CNVs of 1 Mb and  
178 decreased to below 0.25 when detecting CNVs  $\geq 2$  Mb using 5k bins (Figure S3B).

179 To assess the approach's reliability, we investigated the consistency of CNV  
180 profiles between single-cell and bulk populations. We used normal (YH) and tumour  
181 (HeLa S3) cell lines for single-cell copy number analysis and compared the results to  
182 the bulk CNVs from published HeLa S3 [34] and YH data [35]. HeLa S3 cells are  
183 known to harbour germline CNVs of defined sizes. The CNV profiles of single HeLa  
184 S3 cells were similar to the bulk data; however, this analysis did not detect a deletion  
185 on chromosome 4 posted in bulk HeLa S3 DNA (Figure 3A and S3C). We also  
186 observed different copy number states in chromosomes 13 and 18, which agreed with

187 Liu's discovery of substantial heterogeneity between HeLa variants from other  
188 laboratories [36]. The YH cells were B cells from a healthy donor, who was  
189 considered without significant CNVs. As expected, the single-cell YH cell CNV  
190 profile only had minor point CNV fluctuations (**Figure 3B** and S3C).

191 We then applied scDPN to an HCC tumour sample as well as paired ANT. The  
192 bulk tumour sample and peripheral blood mononuclear cells from the same patient  
193 (HCC01) were also subjected to whole-exome sequencing. We obtained 58 cells from  
194 HCC tumour tissue and 10 cells from ANT after filtering (> 300k reads, MAPD <  
195 0.45). All 10 cells from ANT had no significant CNVs, as expected. One cell in the  
196 tumour did not have any CNVs and was considered normal (Figure S3C). The other  
197 57 tumour cells had gain in 2p25.3-2p16.2, loss at 10q, and 56 had 8q11.23-8q24.3  
198 gain (**Figure 3C** and S3C). This result indicated that there was only one major tumour  
199 clone in the HCC01 primary tumour. By comparing a representative copy number  
200 profile of a HCC tumour cell with a bulk CNV profile inferred from whole exome  
201 sequencing data (Materials and Methods), we observed concordant chromosome  
202 duplications of chromosomes 2, 8, and 12 and a deletion on chromosome 10,  
203 verifying the reliability of our CNV data. For example, the CNV profiles revealed  
204 multiple copy alterations, including 2p25.3-2p16.2, and 8q11.23-8q24.3, which are  
205 also present in the bulk DNA (Figure 3C).

## 206 **Single-cell CNV detection reveals tumour clonal subtypes in HCC**

207 Genetic heterogeneity in HCC has been described in somatic nucleotide variations  
208 (SNVs) by NGS or SNP array of multiple regions from the same primary HCC bulk  
209 tumour tissue [37], but there are few studies at the single-cell level. Thus, we used  
210 scDPN to investigate tumour subclones in patient HCC02. After quality control  
211 (UMDR  $\geq 0.30$  M, MAPD  $\leq 0.45$ ), we obtained 106 cells from the primary tumour  
212 for subsequent CNV calling. Three cells without chromosome copy number  
213 alterations were designated as normal cells. The remaining 103 cells showed two  
214 distinct CNV patterns, indicating that at least two tumour clones existed in this

215 primary tumour (**Figure 4A**). The major subpopulation consisted of 87 cells with  
216 high-level amplifications on chromosomes 5p15.33-q35.3, 6p25.3-q12, 7p22.3-q36.3,  
217 8q11.1-q24.3, and 15q11.2-q26.3 and deletions on chromosomes 6q12-q27 and  
218 8p23.3-p11.21. Deletions of chromosomes 6q and 8p and gains in 6p and 8q are  
219 known recurrent CNVs in HCC [38]. A minor subpopulation of HCC02 comprised  
220 16/103 (15.5%) tumour cells and had additional alterations: chromosome 1q21.1-q44  
221 gain, 10q11.21-q23.31 loss, and 14q32.2-q32.33 loss (**Figure 4B**). We also observed  
222 common alterations in chromosomes 5, 6, 7, 8, and 15 in the same patient's bulk  
223 tumour. However, the unique alterations in chromosomes 1, 10, and 14 found in the  
224 minor population of single cells were not detectable in the bulk tumour,  
225 demonstrating the capability of characterizing minor clones in single cells.

226 **Clonal selection in HCC recurrence**

227 A high recurrence rate is one of the risk factors contributing to the low 5-year survival  
228 rate in HCC. Understanding the clonal evolution and selection that occurs during  
229 relapse could aid in exploring the mechanism of recurrence. To investigate the  
230 correlation between the primary and recurrent tumour, we applied scDPN to the  
231 recurrent tumour from HCC02. We obtained 118 qualified cells from the recurrent  
232 tumour using the same filtering criteria. To our surprise, except for 4 normal cells  
233 without significant CNVs, the remaining 114 tumour cells had unique CNVs detected  
234 in the minor clone of the primary tumour, including 1q21.1-q44 gain,  
235 10q11.21-q23.31, and 14q32.2-q32.33 loss (Figure S4A). This result strongly  
236 demonstrated that the minor clone in the primary tumour repopulated to be the  
237 dominant clone during relapse in this patient.

238 Furthermore, a hierarchical cluster analysis was conducted on CNVs in  
239 chromosomes 1, 10, and 14, revealing three subpopulations with distinct CNV  
240 patterns (**Figure 4C**). Clone A comprised 81 primary tumour cells with no CNVs on  
241 these three chromosomes and corresponded to the major clone in the primary tumour.  
242 Both clones B and C showed similar CNVs in these three regions. Clone B was

243 composed of 17 primary tumour cells and 12 recurrent tumour cells and was  
244 considered to be a transitional state of clone C. Clone C consisted of 102 relapsed  
245 tumour cells and 5 primary tumour cells, indicating that the minor clone in the  
246 primary tumour developed into a dominant clone during HCC relapse.

247 To determine which characteristics were associated with clone C selection during  
248 recurrence, we investigated the genes located in these unique CNV regions. We found  
249 several oncogenes and tumour suppressor genes described in the Catalogue Of  
250 Somatic Mutations In Cancer (COSMIC) database (Table S3). Several oncogenes  
251 were located in the amplification regions on chromosome 1q21.1-q44, including  
252 *ABL2*, *BCL9*, *DDR2*, *FCGR2B*, *ELK4*, and *MDM4*, while several tumour suppressor  
253 genes, including *PTEN*, *FAS*, and *PRF1*, were located in the loss region of  
254 10q11.21-q23.31. We further validated that patients with 10q11.21-q23.31 loss or all  
255 the three alterations (1q21.1-q44 gain, 10q11.21-q23.31, and 14q32.2-q32.33 loss)  
256 showed lower disease or progression-free survival rate within two years in the TCGA  
257 dataset for HCC (Figure S4B). However, we did not observe a significant difference  
258 between patients with 1q21.1-q44 gain/14q32.2-q32.33 loss vs. others in disease-free  
259 survival, suggesting that the loss of 10q11.21-q23.31 may make a substantial  
260 contribution to tumour clone selection during relapse in HCC.

261

## 262 **Discussion**

263 Single-cell genomic technologies have greatly aided the analysis of the evolution  
264 of cancer genomes and the study of genetic heterogeneity in cancer. However, the  
265 lack of high-throughput, cost-effective single-cell WGS approaches has limited their  
266 application. Here, we developed a preamplification-free, microwell-based single-cell  
267 DNA library preparation approach named scDPN, which can handle up to 1,800 cells  
268 per run. A fluorescence and imaging system enabled us to select a single and viable  
269 cell accounting for a lower doublet rate. Through a series of experiments, we  
270 determined the optimum on-chip experimental conditions for high data quality. The

271 strategy for constructing libraries of scDPN was similar to the DLP and TnBC  
272 approaches. Improved version of LIANTI (sci-L3) and DLP (DLP+) [39] reported  
273 recently also have increased the throughput.

274 Compared with MDA methods, our platform generated single-cell genome data  
275 with better uniformity and lower noise, which decreases the required sequencing  
276 depth. Low-depth single-cell genome data of the HeLa S3 and YH cell lines and  
277 tumour samples generated by scDPN showed high sensitivity (only  $0.02 \times$  depth data  
278 needed) and accuracy compared with bulk tumour analysis. The small reaction  
279 volume substantially reduced the library construction costs to \$0.5 per cell. ScDPN  
280 has the advantages of amplification uniformity, throughput, and cost over existing  
281 single-cell CNV detection methods. Additionally, we evaluated the performance of  
282 CNV detection in the cell nuclei from frozen tissues (Figure S5), which extends the  
283 application to additional cell types, including neurons and retrospective studies using  
284 frozen tissues.

285 However, scDPN is not suitable for SNVs detection due to low genome coverage.  
286 According to Zahn's study, sequencing reads from all cells can be merged to produce  
287 a 'pseudo-bulk' genome with deep coverage accountable to an inference of SNV.  
288 Otherwise, a collection of high-depth 'clonal genomes' can be generated by  
289 combining all cells within a clone [23]. Additionally, there is a large difference in the  
290 amount of data among single-cell libraries produced from the same run due to the  
291 differential reaction efficiency during library preparation. Therefore, further condition  
292 optimization is essential to obtain uniform library products from an individual cell.

293 We used scDPN to identify subgroups of HCC tumour cells that were not detected  
294 in the bulk population (Figure 4A). This analysis indicates that important information  
295 is missing from bulk level-based sequencing studies. A large cohort based on scCNV  
296 in HCC may be needed to understand the genetic variance and heterogeneity more  
297 comprehensively. Understanding the clonal selection mechanisms in HCC recurrence  
298 could guide treatment and reduce relapse in HCC. Scaling our single-cell DNA

299 preparation approach with paired primary and relapsed tumour samples could address  
300 essential questions concerning subclonal dynamics, such as how specific subclones  
301 evolve, evade immune surveillance, and metastasize.

302 In the profiling of CNVs in paired primary tumour cells (n = 103) and relapsed  
303 HCC tumour cells (n = 114), we observed a subpopulation (clone C) as the minor  
304 clone (5/103, 4.8%) in the primary tumour. This minor clone had additional CNVs of  
305 1q21.1-q44 gain, 10q11.21-q23.31 loss, and 14q32.2-q32.33 loss, which developed  
306 into the dominant clone (102/114, 90%) in the recurrent tumour (Figure 4C). This is  
307 solid evidence to support the tumour clonal selection during HCC relapse (**Figure**  
308 **4D**). We validated in TCGA data that the loss of 10q11.21-q23.31, a region  
309 containing several tumour suppressor genes, is frequent in HCC and may play a  
310 crucial role in tumour clone selection during relapse. A chromosome 8p deletion has  
311 been correlated with HCC metastasis [40] and exists 3 clones in this tumour. The loss  
312 of 6p25.3-q12 presented in all clones would result in loss of heterozygosity (LOH)  
313 across the major histocompatibility complex (MHC), which is also reported to be  
314 associated with cancer metastasis [41]. Immune pressure has been proposed to shape  
315 the clonal evolution of metastasis [42]. However, the drivers or critical factors  
316 contributing to clonal selection during recurrence or metastasis in HCC and other  
317 cancers remain unclear. High-throughput single-cell omics from a large set of cancer  
318 patients, may potentially address these questions and simultaneously dissect the  
319 tumour environment, as well as the genetic and transcriptome characteristics of  
320 tumour cells.

321

## 322 **Materials and methods**

### 323 **Cell line and patient tissue samples**

324 The lymphoblastic cell line (YH cell line) was established from an Asian genome  
325 donor [35]. We purchased the HeLa S3 cell line from the American Type Culture  
326 Collection (CCL-2.2, ATCC, Manassas, VA, USA). The tumour sample used for

327 on-chip reaction determination was a resected sample of a 45-year-old male patient  
328 (HCC01) with a primary HCC tumour. Paired primary and relapsed HCC tumour  
329 samples were obtained from a 63-year-old male patient (HCC02). Peripheral white  
330 blood cells and paired tumour sample and adjacent normal liver tissue were also  
331 obtained for bulk whole-exome sequencing or whole-genome sequencing.

332 **Preparation of the single-cell suspension**

333 Cell suspension of cell lines were harvested and centrifuged at 500 g for 5 min,  
334 washed by phosphate buffer solution (PBS) buffer twice, and resuspended in PBS.  
335 The resected tumour samples were processed to a single-cell suspension using the  
336 commercial Tumour Dissociation Kit (30095929, Miltenyi Biotec, Bergisch  
337 Gladbach, Germany). Briefly, fresh tumour and adjacent normal liver tissues were cut  
338 into approximately 2-4 mm pieces and transferred into the gentleMACS C Tube  
339 containing the enzyme mix. Subsequently, the suspended cells were centrifuged at  
340 300 g for 7 min after passing through cell strainers. The suspended cells were passed  
341 through cell strainers and centrifuged at 300 g for 7 min. The cell pellets were  
342 resuspended in 90% fetal bovine serum (FBS; 10270106, ThermoFisher Scientific,  
343 Waltham, MA, USA) with 10% dimethyl sulfoxide (DMSO; D8418-50ML,  
344 Sigma-Aldrich, St. Louis, MO, USA) and collected in a freezing container for -80 °C  
345 storage.

346 **Single-cell DNA library preparation and sequencing**

347 We used the ReadyProbes Cell Viability Imaging Kit (R37609, ThermoFisher  
348 Scientific, Waltham, MA, USA) that contained Hoechst and PI to identify living cells.  
349 This staining process was at 37 °C for 20 min, then washed in cold 0.5× PBS twice.  
350 For cells from tumour tissue, we added fluorescent antibody CD45 (55548, BD  
351 Pharmingen™, San Jose, CA, USA) in the staining step. Based on FACS, CD45<sup>+</sup>  
352 Hoechst<sup>+</sup> PI cells from the single-cell suspension were sorted into single tubes for  
353 tumour cell enrichment. Counted cells were dispensed into microwells using the  
354 ICELL8 MSND (640000, Takara Bio USA, Mountain View, CA, USA) at the

355 concentration of 25 cells/ $\mu$ l in 0.5 $\times$  PBS and 1 $\times$  Second Diluent (640202, Takara Bio  
356 USA, Mountain View, CA, USA) into the ICELL8 $\circledR$  350v Chip (640019, Takara Bio  
357 USA, Mountain View, CA, USA). We used the mixed buffer of PBS and fiducial mix  
358 (640202, Takara Bio USA, Mountain View, CA, USA) as the negative control wells.  
359 The MSND precisely dispensed 50 nL volumes into the microwells. Following cell  
360 dispensing, the chip was sealed with imaging film and centrifuged for 5 min at 500 g  
361 at 4 °C, and imaged with a 4 $\times$  objective using Hoechst and PI. Following imaging, 35  
362 nL cell lysis buffer was added to each microwell (P1: 2.89 AU/L Protease K (19155,  
363 Qiagen, Germany) and 72.8 mM pH 7.5 Tris-HCl (15567027, ThermoFisher  
364 Scientific, Waltham, MA USA ); P2: 8.67 AU/L Protease K and 72.8 mM pH 7.5  
365 Tris-HCl). The sealed chip was centrifuged for 3 min at 3,000 g and room temperature,  
366 then incubated at 50 °C for 1 h, followed by 75 °C for 20 min and finally 80 °C for 5  
367 min to inactivate the protease. The chip was centrifuged for 3 min at 3,000 g again  
368 before 50 nL Tn5 transposition mix (T1: 0.06 U/ $\mu$ L Tn5 transposase (1000007867,  
369 MGI, China) and 2.4 $\times$  TAG buffer (1000013442, MGI, China); T2: 2.4 $\times$  TAG buffer,  
370 0.14 U/ $\mu$ L Tn5 transposase; T3: 2.4 $\times$  TAG buffer and 0.22 U/ $\mu$ L Tn5 transposase)  
371 were dispensed. After sealed, the chip was centrifuged at the same condition with the  
372 last step and incubated at 55 °C for 30 min. To stop transposase activity, 31 nL 5 $\times$  NT  
373 buffer (0.25% SDS solution), 1.45 nL ddH<sub>2</sub>O, and 2.55 nL of Ad153-forward-tag  
374 (1~72) primer [1  $\mu$ M] were dispensed, centrifuged and incubated for 5 min at room  
375 temperature. Another barcode primer was added to 50 nL PCR mix1 (29.6 nL 5 $\times$   
376 KAPA Fidelity Buffer, 7.69 nL 10 mM each dNTP, 5.1 nL PhoAd153 forward primer  
377 [10  $\mu$ M], 5.1 nL Ad153 reverse primer [10  $\mu$ M], and 2.55 nL of 72 Ad153-reverse-tag  
378 (1~72) primer [1  $\mu$ M] made by KAPA HiFi HotStart PCR Kit (KK2500, Kapa  
379 Biosystems, Cape Town, South Africa). Finally, 50 nL PCR mix2 containing 21.4 nL  
380 5 $\times$  KAPA Fidelity Buffer, 5.1 nL 1 U/ $\mu$ L KAPA HiFi DNA polymerase, and 23.5 nL  
381 ddH<sub>2</sub>O was dispensed. We used the following conditions to perform PCR: 72 °C for 5  
382 min; 95 °C for 3 min; 25 cycles of 98 °C for 3 min for 20 sec, 60 °C for 15 sec, and

383 72 °C for 25 sec; 72 °C for 5 min; and finally 4 °C. The final extraction of PCR  
384 products was carried out by centrifuging at 3,000 g for 3 min with an extraction kit.  
385 Product purification was performed using a 1.0× Agencourt Ampure XP bead  
386 (A63881, Beckman Coulter, Indianapolis, IN, USA) to sample ratio. Following  
387 ssDNA cyclization, digestion, and PEG32 bead purification (1000005259, MGI,  
388 China), the libraries were sequenced in SE100 on the BGISEQ-500 sequencer.

389 **Preprocessing of sequencing data**

390 The raw reads derived from BGISEQ-500 were assessed by SOAPnuke (v1.5.6) [43]  
391 using the parameters “-Q 2 -G”. Afterward, we mapped the qualified reads to the  
392 human reference genome (hg19) by Burrows-Wheeler Aligner (BWA, v0.7.16a) [44]  
393 with BWA-MEM algorithms using arguments “-t 2 -k 32 -M /path/to/ref.fa”. The  
394 output SAM files were compressed and sorted by reference coordinates and then  
395 indexed with SAMtools (v1.1.19) [45]. Subsequently, uniquely mapped reads were  
396 extracted. Reads considered “PCR duplications” were removed by “samtools rmdup”  
397 from the downstream analysis.

398 **Detection of copy number variations**

399 We calculated the copy number of each cell with an optimized method developed by  
400 the Baslan et.al. [35, 46, 47]. Based on the coverage suggestion of 30-180 reads per  
401 window for CNV calling from Gusnanto et al., we estimated the number of bins  
402 according to the average sequencing depth (< 1 Mbp) by the R package NGSoftwin  
403 [48]. The “bin boundaries” files for 5,000 bins in hg19 that suited the read length of  
404 100 bp were generated. After GC content normalization, DNAcopy was employed for  
405 segmentation and copy number calculation, which points to gains and losses in  
406 chromosomes.

407 The FASTQ files of bulk HeLa S3 were downloaded from the NCBI Sequence  
408 Read Archive repository (SRP028541). The YH dataset was available in the  
409 GigaScience repository, GigaDB (<http://gigadb.org/dataset/100115>) [35].

410 For the matched bulk WES dataset, snp-pileup from htstools was first employed  
411 for processing BAM files using parameters “/path/to/dbsnp\_150.common.hg38.vcf.gz  
412 -g -q15 -Q20 -P100 -r25,0”. We then used facets [49] for copy number estimation  
413 from the paired (normal/tumour) samples.

414 **Accuracy of CNV detection from the low coverage single-cell WGS data**

415 The accuracies of CNV calling in the paper were assessed by sensitivity and FDR  
416 gain from the simulated dataset. A series of rearranged genomes with a defined size of  
417 CNVs was randomly generated by SimulateCNVs [50]. In each of the 10 outputs, 0.1  
418  $\times$  WGS datasets with 20 CNVs of a specific size (1, 2, 3, 5, 10, 15 Mbp) were used to  
419 randomly extract  $3 \times 10^5$  uniquely mapped reads after duplicate removal with 5  
420 replicates. A detected CNV was assumed to be true when it overlapped with at least  
421 50% of the simulated CNVs. The sensitivity was defined as TP/(TP + FN), where the  
422 numerator was the true positive CNV mentioned above, while the total number of  
423 CNVs simulated served as the denominator. FDR was defined as FP/(FP+TP), where  
424 the numerator was the false positive CNV, and the denominator was the total number  
425 of CNVs detected by the algorithm.

426 **Estimation of sequencing saturations**

427 The uniquely mapped reads after duplicate removal were randomly down-sampled to  
428  $3 \times 10^4$ ,  $6 \times 10^4$ ,  $9 \times 10^4$ ,  $1.2 \times 10^5$ ,  $1.5 \times 10^5$ ,  $1.8 \times 10^5$ ,  $2.1 \times 10^5$ ,  $2.4 \times 10^5$ ,  $2.7 \times$   
429  $10^5$ ,  $3 \times 10^5$ ,  $4.5 \times 10^5$ ,  $6.5 \times 10^5$ ,  $1.05 \times 10^6$ ,  $1.5 \times 10^6$ , and  $2 \times 10^6$  reads. We used  
430 the down-sampled reads to estimate the sequencing saturation for our low-coverage  
431 WGS method. After calculating the copy number of each bin in the down-sampled  
432 datasets, the boundaries of the bins with copy number unequal to 2 were compared to  
433 that of samples with the highest read depth. The percentages of bins with abnormal  
434 copy number in samples with the highest coverage found in the down-sampled  
435 datasets were recorded. The saturation curves were fitted with locally weighted  
436 (LOESS) regression in geom\_smooth function in the R package ggplot2 [51]. The  
437 inflection point of the curves was considered as the saturation point.

438 **Evaluation of the uniformity**

439 The FASTQ files of MDA, DOP-PCR, MALBAC, LIANTI, TnBC, and sci-L3  
440 datasets were downloaded from the NCBI Sequence Read Archive repository  
441 (SRR504711 for single-cell MDA, SRR1006146 for DOP-PCR, SRR975229 for  
442 MALBAC, SRX2660685 for LIANTI, SRX2847396 for TnBC, SRX5179905 for  
443 sci-L3) respectively. The sequence generated by 10x genomics platform was derived  
444 from [https://support.10xgenomics.com/single-cell-dna/datasets/1.1.0/bj\\_cells\\_1k](https://support.10xgenomics.com/single-cell-dna/datasets/1.1.0/bj_cells_1k).

445 The uniquely mapped reads after duplicate removal from all samples were  
446 randomly down-sampled to  $10^5$  reads for uniformity evaluation. To better indicate the  
447 bias of amplification methods, we binned reads into 60kb intervals across the genome  
448 with an average of 20 reads per bin according to the results from Xi et al. [24]. Reads  
449 in each bin were counted by bedtools2 (v2.20.1) and then applied for Lorenz model  
450 estimation.

451 **CNV profiling and tumor evolution visualization**

452 MAPD is used for noise assessment in CNV calling [47, 52]. Since higher MAPD  
453 values reflect the poorer quality of a cell, we excluded single-cell samples with  
454  $\text{MAPD} > 0.45$ . Segment ratios of samples were presented and clustered by hclust  
455 using ‘ward.D2’. Fishplot [53] was employed for fishplot construction.

456

457 **Ethical statements**

458 We clarified that no animals were involved in this study. All samples involved in  
459 human beings were obtained after written informed consent and approval from the  
460 Institutional Review Board (IRB) at Fudan University ZhongShan Hospital and  
461 BGI-Shenzhen.

462 **Data availability**

463 The low-coverage WGS data generated by BGISEQ-500 were deposited at CNGB  
464 Nucleotide Sequence Archive (<https://db.cngb.org/>) with the accession ID  
465 CNP0000448 and GSA at the National Genomics Data Centre (<https://bigd.big.ac.cn/>)  
466 with the accession ID HRA000478 and HRA000476.

467 **CRedit author statement**

468 **Liang Wu:** Conceptualization, Methodology, Investigation, Writing-Original Draft,  
469 Writing-Review & Editing, Supervision. **Yuzhou Wang:** Methodology, Investigation,  
470 Writing-Original Draft. **Miaomiao Jiang:** Software, Data Curation, Investigation,  
471 Writing-Original Draft, Writing-Review & Editing, Visualization. **Biaofeng Zhou:**  
472 Software, Data Curation, Visualization. **Yunfan Sun:** Resources. **Kaiqian Zhou:**  
473 Resources. **Jiarui Xie:** Visualization. **Yu Zhong:** Software. **Zhikun Zhao:**  
474 Writing-Review & Editing. **Michael Dean:** Writing-Review & Editing. **Yong Hou:**  
475 Supervision, Project administration. **Shiping Liu:** Supervision, Project  
476 administration, Funding acquisition. All authors read and approved the final  
477 manuscript.

478 **Competing interests**

479 No conflicts of interest are declared.

480 **Acknowledgements**

481 This work was supported by Technology and Innovation Commission of Shenzhen  
482 Municipality (Grant No. GJHZ20180419190827179), and Science, Technology and  
483 Innovation Commission of Shenzhen Municipality (Grant No.  
484 JCYJ20170303151334808). We sincerely thank the support provided by China

485 National GeneBank. We thank Dr. Xiaoyun Huang for the helpful comments on the  
486 manuscript. We are also grateful to Lei Li and Shishang Qin for assistance in data  
487 analysis as well as Dandan Chen for experimental support.

488 **Authors' ORCID IDs**

489 0000-0001-6259-261X (Liang Wu), 0000-0003-0033-6383 (Yuzhou Wang),  
490 0000-0002-8473-8955 (Miaomiao Jiang), 0000-0002-0261-8256 (Biaofeng Zhou),  
491 0000-0001-9790-2761 (Yunfan Sun), 0000-0002-2763-5976 (Kaiqian Zhou),  
492 0000-0001-9022-4881 (Jiarui Xie), 0000-0001-6902-2732 (Yu Zhong),  
493 0000-0001-5161-7818 (Zhikun Zhao), 0000-0003-2234-0631(Michael Dean),  
494 0000-0002-0420-0726 (Yong Hou), 0000-0003-0019-619X (Shiping Liu).

495

496 **References**

497 [1] Lawson DA, Kessenbrock K, Davis RT, Pervolarakis N, Werb Z. Tumour  
498 heterogeneity and metastasis at single-cell resolution. *Nat Cell Biol* 2018;20:1349-60.

499 [2] Macaulay IC, Voet T. Single cell genomics: advances and future perspectives.  
500 *PLoS Genet* 2014;10:e1004126.

501 [3] Shapiro E, Biezuner T, Linnarsson S. Single-cell sequencing-based technologies  
502 will revolutionize whole-organism science. *Nat Rev Genet* 2013;14:618-30.

503 [4] Gawad C, Koh W, Quake SR. Single-cell genome sequencing: current state of the  
504 science. *Nat Rev Genet* 2016;17:175-88.

505 [5] Patel AP, Tirosh I, Trombetta JJ, Shalek AK, Gillespie SM, Wakimoto H, et al.  
506 Single-cell RNA-seq highlights intratumoral heterogeneity in primary glioblastoma.  
507 *Science* 2014;344:1396-401.

508 [6] Tirosh I, Izar B, Prakadan SM, Wadsworth MH, 2nd, Treacy D, Trombetta JJ, et  
509 al. Dissecting the multicellular ecosystem of metastatic melanoma by single-cell  
510 RNA-seq. *Science* 2016;352:189-96.

511 [7] Chevrier S, Levine JH, Zanotelli VRT, Silina K, Schulz D, Bacac M, et al. An  
512 immune atlas of clear cell renal cell carcinoma. *Cell* 2017;169:736-49.

513 [8] Azizi E, Carr AJ, Plitas G, Cornish AE, Konopacki C, Prabhakaran S, et al.  
514 Single-cell map of diverse immune phenotypes in the breast tumor microenvironment.  
515 *Cell* 2018;174:1293-308.

516 [9] Lavin Y, Kobayashi S, Leader A, Amir ED, Elefant N, Bigenwald C, et al. Innate  
517 immune landscape in early lung adenocarcinoma by paired single-cell analyses. *Cell*  
518 2017;169:750-65.

519 [10] Lambrechts D, Wauters E, Boeckx B, Aibar S, Nittner D, Burton O, et al.  
520 Phenotype molding of stromal cells in the lung tumor microenvironment. *Nat Med*  
521 2018;24:1277-89.

522 [11] Guo X, Zhang Y, Zheng L, Zheng C, Song J, Zhang Q, et al. Global  
523 characterization of T cells in non-small-cell lung cancer by single-cell sequencing.  
524 Nat Med 2018;24:978-85.

525 [12] Puram SV, Tirosh I, Parikh AS, Patel AP, Yizhak K, Gillespie S, et al.  
526 Single-cell transcriptomic analysis of primary and metastatic tumor ecosystems in  
527 head and neck cancer. Cell 2017;171:1611-24.

528 [13] Li H, van der Leun AM, Yofe I, Lubling Y, Gelbard-Solodkin D, van Akkooi  
529 ACJ, et al. Dysfunctional CD8 T cells form a proliferative, dynamically regulated  
530 compartment within human melanoma. Cell 2019;176:775-89.

531 [14] Johnson BE, Mazor T, Hong C, Barnes M, Aihara K, McLean CY, et al.  
532 Mutational analysis reveals the origin and therapy-driven evolution of recurrent  
533 glioma. Science 2014;343:189-93.

534 [15] Wang Y, Waters J, Leung ML, Unruh A, Roh W, Shi X, et al. Clonal evolution  
535 in breast cancer revealed by single nucleus genome sequencing. Nature  
536 2014;512:155-60.

537 [16] Navin N, Kendall J, Troge J, Andrews P, Rodgers L, McIndoo J, et al. Tumour  
538 evolution inferred by single-cell sequencing. Nature 2011;472:90.

539 [17] Hou Y, Song L, Zhu P, Zhang B, Tao Y, Xu X, et al. Single-cell exome  
540 sequencing and monoclonal evolution of a JAK2-negative myeloproliferative  
541 neoplasm. Cell 2012;148:873-85.

542 [18] Xu X, Hou Y, Yin X, Bao L, Tang A, Song L, et al. Single-cell exome  
543 sequencing reveals single-nucleotide mutation characteristics of a kidney tumor. Cell  
544 2012;148:886-95.

545 [19] Zhang L, Cui X, Schmitt K, Hubert R, Navidi W, Arnheim N. Whole genome  
546 amplification from a single cell: implications for genetic analysis. P Natl Acad Sci  
547 USA 1992;89:5847-51.

548 [20] Spits C, Le Caignec C, De Rycke M, Van Haute L, Van Steirteghem A, Liebaers  
549 I, et al. Whole-genome multiple displacement amplification from single cells. *Nat*  
550 *Protoc* 2006;1:1965-70.

551 [21] Zong C, Lu S, Chapman AR, Xie XS. Genome-wide detection of  
552 single-nucleotide and copy-number variations of a single human cell. *Science*  
553 2012;338:1622-6.

554 [22] Chen C, Xing D, Tan L, Li H, Zhou G, Huang L, et al. Single-cell whole-genome  
555 analyses by Linear Amplification via Transposon Insertion (LIANTI). *Science*  
556 2017;356:189-94.

557 [23] Zahn H, Steif A, Laks E, Eirew P, VanInsberghe M, Shah SP, et al. Scalable  
558 whole-genome single-cell library preparation without preamplification. *Nat Methods*  
559 2017;14:167.

560 [24] Xi L, Belyaev A, Spurgeon S, Wang X, Gong H, Aboukhalil R, et al. New  
561 library construction method for single-cell genomes. *PLoS one* 2017;12:e0181163.

562 [25] Roayaie S, Obeidat K, Sposito C, Mariani L, Bhoori S, Pellegrinelli A, et al.  
563 Resection of hepatocellular cancer <=2 cm: results from two Western centers.  
564 *Hepatology* 2013;57:1426-35.

565 [26] Lu LC, C.-H H, Hsu C, Cheng AL. Tumor heterogeneity in hepatocellular  
566 carcinoma: facing the challenges. *Liver Cancer* 2016;5:128-38.

567 [27] Friemel J, Rechsteiner M, Frick L, Bohm F, Struckmann K, Egger M, et al.  
568 Intratumor heterogeneity in hepatocellular carcinoma. *Clin Cancer Res*  
569 2015;21:1951-61.

570 [28] Xue R, Li R, Guo H, Guo L, Su Z, Ni X, et al. Variable intra-tumor genomic  
571 heterogeneity of multiple lesions in patients with hepatocellular carcinoma.  
572 *Gastroenterology* 2016;150:998-1008.

573 [29] Hou Y, Guo H, Cao C, Li X, Hu B, Zhu P, et al. Single-cell triple omics  
574 sequencing reveals genetic, epigenetic, and transcriptomic heterogeneity in  
575 hepatocellular carcinomas. *Cell Res* 2016;26:304-19.

576 [30] Duan M, Hao J, Cui S, Worthley DL, Zhang S, Wang Z, et al. Diverse modes of  
577 clonal evolution in HBV-related hepatocellular carcinoma revealed by single-cell  
578 genome sequencing. *Cell Res* 2018;28:359-73.

579 [31] Natarajan KN, Miao Z, Jiang M, Huang X, Zhou H, Xie J, et al. Comparative  
580 analysis of sequencing technologies for single-cell transcriptomics. *Genome Biol*  
581 2019;20:1-8.

582 [32] Garvin T, Aboukhalil R, Kendall J, Baslan T, Atwal GS, Hicks J, et al.  
583 Interactive analysis and assessment of single-cell copy-number variations. *Nat  
584 Methods* 2015;12:1058-60.

585 [33] Yin Y, Jiang Y, Lam KG, Berletch JB, Disteche CM, Noble WS, et al.  
586 High-throughput single-cell sequencing with linear amplification. *Mol Cell*  
587 2019;76:676-90.

588 [34] Adey A, Burton JN, Kitzman JO, Hiatt JB, Lewis AP, Martin BK, et al. The  
589 haplotype-resolved genome and epigenome of the aneuploid HeLa cancer cell line.  
590 *Nature* 2013;500:207-11.

591 [35] Hou Y, Wu K, Shi X, Li F, Song L, Wu H, et al. Comparison of variations  
592 detection between whole-genome amplification methods used in single-cell  
593 resequencing. *Gigascience* 2015;4:s13742-015.

594 [36] Liu Y, Mi Y, Mueller T, Mueller, T., Kreibich, S., Williams, E. G., Van Drogen,  
595 A., et al. Multi-omic measurements of heterogeneity in HeLa cells across laboratories.  
596 *Nat Biotechnol* 2019;37:314-22.

597 [37] Ling S, Hu Z, Yang Z, Yang F, Li Y, Lin P, et al. Extremely high genetic  
598 diversity in a single tumor points to prevalence of non-Darwinian cell evolution. *P  
599 Natl Acad Sci USA* 2015;112:E6496-505.

600 [38] Chen L, Chan TH, Guan XY. Chromosome 1q21 amplification and oncogenes in  
601 hepatocellular carcinoma. *Acta Pharmacol Sin* 2010;31:1165-71.

602 [39] Laks E, McPherson A, Zahn H, Lai D, Steif A, Brimhall J, et al. Clonal  
603 decomposition and DNA replication states defined by scaled single-cell genome  
604 sequencing. *Cell* 2019;179:1207-21.

605 [40] Qin LX, Tang ZY, Sham JS, Ma ZC, Ye SL, Zhou XD, et al. The association of  
606 chromosome 8p deletion and tumor metastasis in human hepatocellular carcinoma.  
607 *Cancer Res* 1999;59:5662-5.

608 [41] McGranahan N, Rosenthal R, Hiley CT, Rowan AJ, Watkins TBK, Wilson GA,  
609 et al. Allele-specific HLA loss and immune escape in lung cancer evolution. *Cell*  
610 2017;171:1259-71.

611 [42] Angelova M, Mlecnik B, Vasaturo A, Bindea G, Fredriksen T, Lafontaine L, et  
612 al. Evolution of metastases in space and time under immune selection. *Cell*  
613 2018;175:751-65.

614 [43] Chen Y, Chen Y, Shi C, Huang Z, Zhang Y, Li S, et al. SOAPnuke: a  
615 MapReduce acceleration-supported software for integrated quality control and  
616 preprocessing of high-throughput sequencing data. *Gigascience* 2017;7:gix120.

617 [44] Li H, Durbin R. Fast and accurate short read alignment with Burrows–Wheeler  
618 transform. *Bioinformatics* 2009;25:1754-60.

619 [45] Li H, Handsaker B, Wysoker A, Fennell T, Ruan J, Homer N, et al. The sequence  
620 alignment/map format and SAMtools. *Bioinformatics* 2009;25:2078-9.

621 [46] Baslan T, Kendall J, Rodgers L, Cox H, Riggs M, Stepansky A, et al.  
622 Genome-wide copy number analysis of single cells. *Nat Protoc* 2012;7:1024.

623 [47] Zhao Z, Goldin L, Liu S, Wu L, Zhou W, Lou H, et al. Evolution of multiple cell  
624 clones over a 29-year period of a CLL patient. *Nat Commun* 2016;7:1-10.

625 [48] Gusnanto A, Taylor CC, Nafisah I, Wood HM, Rabitts P, Berri S. Estimating  
626 optimal window size for analysis of low-coverage next-generation sequence data.  
627 *Bioinformatics* 2014;30:1823-9.

628 [49] Shen R, Seshan VE. FACETS: allele-specific copy number and clonal  
629 heterogeneity analysis tool for high-throughput DNA sequencing. Nucleic Acids Res  
630 2016;44:e131.

631 [50] Xing Y, Dabney AR, Li X, Casola C. SimulateCNVs: a novel software  
632 application for simulating CNVs in WES and WGS data. BioRxiv 2018; 407486.

633 [51] Wickham H. *ggplot2: elegant graphics for data analysis*. Springer, 2016.


634 [52] Ning L, Li Z, Wang G, Hu W, Hou Q, Tong Y, et al. Quantitative assessment of  
635 single-cell whole genome amplification methods for detecting copy number variation  
636 using hippocampal neurons. *Sci Rep* 2015;5:1-3.

637 [53] Miller CA, McMichael J, Dang HX, Maher CA, Ding L, Ley TJ, et al.  
638 Visualizing tumor evolution with the fishplot package for R. *BMC Genomics*  
639 2016;17:880.

640

641 **Figures**

642



643


644 **Figure 1 Schematic diagram of microwell-based single-cell genomic DNA**  
645 **library preparation**

646 Stained cell suspensions were automatically dispensed into  $72 \times 72$  microwell chips  
647 using MSND. Scanning fluorescence microscopy and cell selection software were  
648 used to discriminate wells containing single cells via the fluorescence of Hoechst and  
649 PI dyes. In the selected microwells, lysis buffer, Tn5 fragmentation buffer and  $72 \times$   
650  $72$  barcode primers were added step by step for single-cell DNA library amplification.  
651 The chip was incubated in a thermal cycler after each step. Indexed single-cell  
652 libraries were pooled by centrifugation for library purification, cyclized, and

653 sequenced on the BGISEQ500 platform. PI, propidium iodide. MSND, MultiSample

654 NanoDispenser.

655




656

657 **Figure 2 Assessment of library quality under different experimental conditions**

658 A. CNV saturation curve. The detected CNVs increased with increasing numbers of  
659 unique mapped reads. At 300k reads, the CNV counts reach saturation. B. Sequencing  
660 data overview of 5 different single-cell lysis and transposase fragmentation conditions  
661 (T1\_P1, n = 28; T2\_P1, n = 22; T2\_P2, n = 10; T3\_P1, n = 3; T3\_P2, n = 9). Violin  
662 charts showing the distribution of MAPD\_5k and duplication ratio in different  
663 conditions with 400k raw reads. The Student's T test was performed. C. Comparison  
664 of different library preparation conditions and the MDA method using Lorenz curves  
665 shows genome-wide coverage uniformity. The dotted straight black line indicates a

666 perfectly uniform genome. **D.** Comparison of different library preparation methods  
667 (DOP-PCR, MALBAC, LIANTI, TnBC, sci-L3, and the 10x genomics) using Lorenz  
668 curves shows genome-wide coverage uniformity. The dotted straight black line  
669 indicates a perfectly uniform genome. CNV, copy number variation; MDA, multiple  
670 displacement amplification; DOP-PCR, degenerate oligonucleotide-primed PCR;  
671 MALBAC, multiple annealing, and looping-based amplification cycles; LIANTI,  
672 linear amplification via transposon insertion; TnBC, transposon barcoded; sci-L3, a  
673 single-cell sequencing method that combines combinatorial indexing and linear  
674 amplification.

675




676

677 **Figure 3** scDPN provides reliable data for accurate scCNV detection

678 **A.** Single-cell CNV profiles of HeLa S3 cells obtained using the T2\_P1 condition and  
679 the corresponding bulk level HeLa S3 profile from published data. **B.** Single-cell  
680 resolution CNV profiles of the YH cell line obtained from the T2\_P1 condition and  
681 the corresponding bulk level YH profile from published data. **C.** Representative single  
682 tumour cell copy number profile and corresponding bulk tumour CNV profile from  
683 FACETS analysis of whole-exome sequencing data in HCC01. The second panel  
684 plots the corresponding integer (total, minor) copy number calls. The estimated  
685 cellular fraction profile is plotted at the bottom, revealing both clonal and sub-clonal  
686 copy number events. HCC, hepatocellular carcinoma.

687



688

689 **Figure 4** Single-cell CNV profiles reveal tumour clonal selection during HCC  
690 recurrence

691 **A.** Two CNV patterns observed in single-cell and CNV profiles detected by bulk  
692 WGS of the primary tumour in HCC02. Colours correspond to inferred copy-number  
693 states; black lines indicate segment medians. **B.** Heatmap showing the copy number  
694 states of all 106 cells from the primary tumour. Columns correspond to cells, and  
695 rows correspond to a ~600 kb genomic bin for each chromosome. Reported  
696 HCC-related genes *TERT*, *VEGFA*, and *MYC* are indicated. **C.** Heatmap showing the

697 unsupervised clustering of all tumour cells from primary (n = 103) and relapsed  
698 tumours (n = 114) based on the CNVs on chr 1, 10, and 14. **D.** Schematic diagram of  
699 HCC tumour clonal selection during recurrence in patient HCC02.  
700

701 **Supplementary materials**

702 **Figure S1 Quality control of the library construction**

703 The length distribution of the library was determined using an Agilent 2100  
704 bioanalyzer.

705 **Figure S2 Assessment for scDNP under different conditions**

706 **A.** Boxplots showing the distribution of mapped reads and genome coverage, in  
707 different conditions. The Student's T test was performed. **B.** The proportions of HCC  
708 cells (UMDR > 300K) sampled from the same patient with MAPD  $\leq/ > 0.45$  in  
709 different numbers of bins among various lysis and transposase fragmentation  
710 conditions (T1\_P1, n = 22; T2\_P1, n = 15; T2\_P2, n = 5; T3\_P1, n = 2, excluded;  
711 T3\_P2, n = 4).

712 **Figure S3 scDPN provides reliable data for accurate scCNV detection**

713 Sensitivities (**A**) and FDRs (**B**) of the CNV detection algorithm at defined resolutions.  
714 The points and error bars represent the means and standard deviations, respectively.  
715 FDR, false discovery rate. **C.** Single-cell CNVs of different samples using low  
716 coverage. Heatmap showing the CNV profiling of HeLa S3 cells (red), YH cells  
717 (yellow), cells from adjacent liver tissue (blue), and tumour tissue (green) of HCC01.  
718 Columns correspond to cells, and rows correspond to 600 kb genomic bins for each  
719 chromosome. FDR, the false discovery rate.

720 **Figure S4 Tumour clonal selection during HCC recurrence**

721 **A.** Single-cell CNV profiling of HCC02 recurrent tumour samples. Heatmap showing  
722 the CNV profiles of all 118 cells from relapsed tumours. Columns correspond to cells,  
723 and rows correspond to 600 kb genomic bins for each chromosome. **B-C.**  
724 Kaplan-Meier analysis showing the disease/progression-free survival for patients with  
725 chr10q11.21-q23.31 deletion (**B**) and the three alterations (**C**) in the TCGA dataset for  
726 HCC.

727 **Figure S5 Evaluation of our CNV detection method with cell nuclei**

728 The distribution of mapped reads, used reads, genome coverage, and MAPD\_5k of  
729 either the nucleus or cells are shown by box plots, and dots indicate individual  
730 samples. The Student's T test was performed.

731 **Table S1 Statistics of cells used in the adjustment of reaction parameters**

732 **Table S2 Single-cell resource for scDPN assessment and tumour clone analyse**

733 **Table S3 Oncogenes and tumour suppressor genes with copy number  
734 alterations in our study**

735